Guanfacine hydrochloride (Intuniv®)

Assessment Status Assessment process complete
Drug Guanfacine hydrochloride
Brand Intuniv®
Indication For the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6-17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective.  It must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.
Assessment Process
Rapid review commissioned 01/12/2015
Rapid review completed 18/12/2023
Rapid review outcome Full Pharmacoeconomic Evaluation not Recommended.